This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Olubunmi Afonja
Senior Director, Clinical Development at Editas Medicine

Agenda Sessions

  • AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 (reni-cel) Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-dependent Beta-thalassemia